CERATIUM LIMITED

Their core work

Ceratium Limited is a UK-based SME that provides specialist consultancy and technical services across life sciences and plant biotechnology domains. Their work spans clinical trial support for rare diseases (Duchenne Muscular Dystrophy via VISION DMD) and plant science applications including photosynthesis research and biobased economy development. They appear to operate as a flexible third-party expert brought into larger consortia to deliver specific technical or advisory contributions, rather than running their own research programmes.

What they specialise in

How they've shifted over time

Ceratium's early H2020 involvement (2016) centred on health and rare disease clinical trials (VISION DMD) alongside biobased economy work (SUPERBIO). Their more recent activity (2020 onward, CAPITALISE) shifted decisively toward plant science — photosynthesis, phenotyping, plant breeding, and agricultural sustainability. This trajectory suggests a pivot from pharma-adjacent services toward agricultural biotechnology and plant research applications.

Ceratium appears to be moving toward plant biotechnology and sustainable agriculture, making them a potential partner for future agri-food or bio-economy consortia.

How they like to work

Ceratium operates almost exclusively as a supporting player — zero projects as coordinator, two out of three as a third party. They join large consortia (40 unique partners across 13 countries) rather than leading them. This profile suggests they are brought in for specific expertise or services rather than driving project design, making them a low-risk, plug-in contributor for consortium builders who need a particular capability filled.

Despite only three projects, Ceratium has connected with 40 unique partners across 13 countries, indicating involvement in large multinational consortia. Their network breadth relative to project count suggests they are well-embedded in European research ecosystems without being a central hub.

What sets them apart

Ceratium's unusual combination of rare disease clinical trial experience and plant biotechnology expertise is distinctive for a small UK SME. Few organisations bridge health and agricultural biotech in this way. For consortium builders, they offer a versatile third-party contributor who can operate across life science domains and bring commercial translation awareness to research-heavy projects.

Highlights from their portfolio

• VISION DMD
  Their only directly funded project (EUR 467,344), a Phase 2 clinical trial for an innovative steroid-like treatment for Duchenne Muscular Dystrophy — a high-impact rare disease intervention.
• CAPITALISE
  A large-scale plant science project (2020-2024) focused on photosynthesis improvement for European agricultural sustainability, signalling their pivot toward agri-biotech.